For the Inventor, By the Inventor

Enter assignee name

Wayne, PA, United States of America

Aclaris Therapeutics, Inc.

USPTO Granted Patents = 21

% Expired Patents = 28.6

CIPO Patents = 4

EPO Patents = 6

Trademarks = 7

Forward Citations = 35

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Susan Landis Hockerman (9 out of 32 patents)

David R Anderson (8 out of 46 patents)

James Robert Blinn (8 out of 21 patents)

4. Eric Jon Jacobsen (8 out of 46 patents)

5. John Robert Springer (7 out of 12 patents)

6. Marc Barry Brown (6 out of 35 patents)

7. Thomas Nagler (6 out of 8 patents)

8. Michael A Botta (6 out of 20 patents)

9. Stuart D Shanler (6 out of 15 patents)

10. Christopher Powala (6 out of 9 patents)

11. Christopher Phillips (6 out of 12 patents)

12. Brian Beger (6 out of 6 patents)

13. Charles Rodney Greenaway Evans (6 out of 18 patents)

14. Sian Tiong Lim (6 out of 6 patents)

15. Gary A Decrescenzo (6 out of 7 patents)

21 patents: Sort by Forward Citations

1. 12616696 - Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one (2026-05-05),

2. 12403141 - Deuterated MK2 pathway inhibitors and methods of using the same (2025-09-02),

3. 12384757 - Methods of synthesizing substituted pyridinone-pyridinyl compounds (2025-08-12),

4. 12370195 - Oral compositions of MK2 pathway inhibitor for treatment of immune conditions (2025-07-29),

5. 12297203 - Pyrrolopyrimidine ITK inhibitors (2025-05-13),

6. 12281111 - Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same (2025-04-21),

7. 11844801 - Oral compositions of MK2 pathway inhibitor for treatment of immune conditions (2023-12-19),

8. 11820775 - Pyrrolopyrimidine ITK inhibitors (2023-11-21),

9. 11767309 - Methods of synthesizing substituted pyridinone-pyridinyl compounds (2023-09-26),

10. 11739086 - Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same (2023-08-29),

11. 10981906 - Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same (2021-04-20),

12. 10800775 - Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same (2020-10-13),

13. 10729720 - Peroxide formulations and methods and applicators for using the same (2020-08-04),

14. 10653721 - Peroxide formulations and methods and applicators for using the same (2020-05-19),

15. 10493103 - Peroxide formulations and methods and applicators for using the same (2019-12-03),

Company Overview

Aclaris Therapeutics, Inc. is a biopharmaceutical company based in Wayne, Pennsylvania, focused on developing innovative therapies for dermatological and immunological conditions. The company specializes in the research and development of novel treatments that leverage its expertise in immunology and dermatology. Aclaris aims to address unmet medical needs through its pipeline of product candidates, utilizing advanced scientific methodologies to enhance patient outcomes in skin-related disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

21 Patents

#7 in Wayne, PA

#571 in Pennsylvania

#15,712 in US

#30,001 in the World

Wayne, PA, United States of America

Aclaris Therapeutics, Inc.

Forward Citations = 35

27 inventors:

Susan Landis Hockerman (9 out of 32 patents)

David R Anderson (8 out of 46 patents)

James Robert Blinn (8 out of 21 patents)

4. Eric Jon Jacobsen (8 out of 46 patents)

5. John Robert Springer (7 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aclaris Therapeutics, Inc.. Retrieved from https://idiyas.com/company/aclaris-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…